OncoMed Absorbs Double Dose Of Bad News With Trial Failure, Two Options Declined
Executive Summary
The California biotech's Phase II pancreatic cancer candidate demcizumab failed to show benefit versus placebo for progression-free or overall survival. Meanwhile, Bayer decided not to exercise its options on a pair of Wnt pathway candidates under a 2010 collaboration with OncoMed.